Title: Clinical features and progression of acute respiratory distress syndrome in

coronavirus disease 2019

Yanli Liu, MD[1,*]; Wenwu Sun, MD[1,*]; Jia Li, PhD[2,*]; Liangkai Chen, PhD[3,*,#]; Yujun

Wang, MD[1]; Lijuan Zhang, MD[1]; Li Yu, MD[1,#].

[1] Intensive Care Unit, the Central Hospital of Wuhan, Tongji Medical College,

Huazhong University of Science and Technology, Wuhan, China.

[2] Department of Health Technology and Informatics, the Hong Kong Polytechnic

University, Hung Hom, Kowloon, Hong Kong PRC.

[3] Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition

and Safety, Ministry of Education Key Lab of Environment and Health, School of

Public Health, Tongji Medical College, Huazhong University of Science and

Technology, Wuhan, China.

* The first four authors contributed equally to this article.

 # Corresponding authors:

Liangkai Chen, Email: clk@hust.edu.cn;

Li Yu, Email: yuliwhzxyy@163.com.

Word count: 2,188

No. of Tables: 3

No. of Figures: 2

Abstract

Background: The outbreak of severe acute respiratory syndrome coronavirus 2

(SARS-CoV-2) results in a cluster of coronavirus disease 2019 (COVID-19). We

reported the clinical characteristics of COVID-19 patients with acute respiratory

distress syndrome (ARDS), and further investigated the treatment and progression of

ARDS in COVID-19.

Methods: This study enrolled 109 patients with COVID-19 admitted to the Central

Hospital of Wuhan, a designated hospital in Wuhan, China, from January 2 to February

1, 2020. Patients were followed up to February 12, 2020. The clinical data were

collected from the electronic medical records. The differences in the treatment and

progression with the time and the severity of ARDS were determined.

Results: Among 109 patients, mean age was 55 years, and 59 patients were male. With

a median 15 days (range, 4 to 30 days) follow-up period, 31 patients (28.4%) died,

while 78 (71.6%) survived and discharged. Of all patients, 53 (48.6%) developed ARDS.

Compared to non-ARDS patients, ARDS patients were elder (mean age, 61 years *vs.* 49

years), and more likely to have the coexistent conditions, including diabetes (20.8% *vs.*

1.8%), cerebrovascular disease (11.3% *vs.* 0%), and chronic kidney disease (15.1% *vs.*

3.6%). Compared to mild ARDS patients, those with moderate and severe ARDS had

higher mortality rates. No significant effect of antivirus, glucocorticoid, or

immunoglobulin treatment on survival was observed in patients with ARDS.

Conclusions: The mortality rate increased with the severity of ARDS in COVID-19,

and the effects of current therapies on the survival for these patients were not

satisfactory, which needs more attention from clinicians.

Key words: severe acute respiratory syndrome coronavirus 2; coronavirus disease 2019;

acute respiratory distress syndrome; clinical feature; mortality.

Introduction

The emergent outbreaks of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain a threat to the public health worldwide [1,2]. As of February 19, 2020, 74,280 cases were confirmed, and 2,008 death cases were recorded in China. The number of confirmed cases in other countries are ascending as well [3-5]. COVID-19 may become a heavy global burden, especially in the low-income and middle-income countries.

Growing studies identified the clinical features of COVID-19 [6-8]. Similar to SARS in 2003, this infectious disease results in the high possibility of the admission to the intensive care unit (ICU) and the mortality [6]. Notably, due to the cytokine cascade within a short period, the critically ill patients with COVID-19 were more likely to develop acute respiratory distress syndrome (ARDS) and receive oxygen treatment [6]. ARDS was the most common complication in COVID-19 patients, with a high mortality rate [6,7]. However, little is known regarding the clinical characteristics, treatment, and progression of COVID-19 patients who developed ARDS.

In this study, we retrospectively reviewed the clinical data of patients with COVID-19 who were admitted to the Central Hospital of Wuhan, and determined the differences in the clinical characteristics between COVID-19 patients with and without ARDS. Additionally, to reveal the evolvement of ARDS in COVID-19, we also investigated the clinical features and therapies of COVID-19 patients at each severity level of ARDS.

Our study might provide new insight into the risk stratification and therapeutic strategy

for COVID-19 patients.

Methods

Study Population

Between January 2 and February 1, 2020, 109 patients with COVID-19 admitted to the

Central Hospital of Wuhan were consecutively enrolled. The Central Hospital of Wuhan

is one of the designated hospitals set up on a temporary basis to receive patients with

COVID-19. According to the World Health Organization interim guidance [9], the

diagnostic criteria of COVID-19 was based on the virus RNA detection, the clinical

characteristics, the chest imaging, and the ruling out common pathogen. Patients with

malignant tumors, previous craniocerebral operation, died on admission, or transferred

to other medical institutions were excluded. The clinical outcomes of patients were

followed up to February 12, 2020. All data were anonymous, and the requirement for

informed consent was waived. The Ethics Committees of the Central Hospital of Wuhan

approved this study.

Data Collection

Case report forms, nursing records, laboratory findings, and radiological features were

reviewed. All data were collected onto the standardized forms from the electronic

medical records in the hospital. Two senior physicians independently reviewed the data.

Information on demographic data, symptoms, underlying comorbidities, chest

computed tomographic images, and laboratory results were included. All treatment

measures were collected during the hospitalization, such as antiviral therapy,

antibacterial therapy, corticosteroid therapy, immune support therapy, and respiratory

support. The time of disease onset was defined as the day of symptom onset. The time

from the first symptom to the fever clinics, hospital admission, and clinical outcomes

were recorded. A confirmed respiratory tract specimen was defined as positive for

SARS-CoV-2. Repeated tests for SARS-CoV-2 were done in the confirmed patients to

show viral clearance before the hospital discharge. The Berlin definition was applied to

determine the presence and severity of ARDS [10]. Acute Physiology and Chronic Health

Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) scores and

CURB-65 criteria [11] were determined within 24 hours after admission.

Detection of Coronavirus by Real-Time Reverse Transcription Polymerase Chain

Reaction

Throat swab samples were collected from the suspected patients, and the method of

virus RNA detection was reported [7]. Briefly, the presence of SARS-CoV-2 in the

respiratory specimens was detected by real-time reverse transcription polymerase chain

reaction (RT-PCR). Two target genes were used, including open reading frame lab

(ORF1ab) and nucleocapsid protein (N), and the sequences were as follows: ORF1ab:

forward   primer   CCCTGTGGGTTTTACACTTAA;   reverse   primer

ACGATTGTGCATCAGCTGA.   N: forward   primer

GGGGAACTTCTCCTGCTAGAAT;   reverse   primer

CAGACATTTTGCTCTCAAGCTG. The real-time RT-PCR assay was conducted in

line with the manufacturer's protocol (Beijing Genomics Institution and Geneodx

biotechnology Co. Ltd). Positive test results for two target genes were considered as

laboratory-confirmed infection.

Statistical Analysis

Normally distributed continuous variables were presented as mean ± SD, compared by

Student's t-test. Skew distributed continuous variables were shown as median

(interquartile range [IQR]), analyzed by Mann–Whitney test or Kruskal–Wallis test.

Categorical variables were compared by Chi-square test or the Fisher's exact test.

Kaplan–Meier methods were used for survival plotting, and log-rank test for

comparison of survival curves. The dynamic trajectory in laboratory parameters was

plotted using GraphPad Prism 8 (GraphPad Software, Inc). Generalized linear mixed

models examined the differences in the laboratory data between ARDS and non-ARDS

groups over time. All statistical analysis were performed by the statistical software

packages R (http://www.R-project.org, The R Foundation) and the EmpowerStats

(http://www.empowerstats.com, X&Y Solutions, Inc., Boston, MA) with a two-sided

significance threshold of P <0.05.

Results

Clinical Characteristics

A total of 109 patients with COVID-19 were included in the current study. The

baseline clinical parameters of overall COVID-19 patients and COVID-19 patients

with and without ARDS were summarized in **Table 1**. Mean age of all subjects was

55 years (IQR, 43-66 years; range, 22-94 years), and 54.1% of all patients were male.

The most common symptom at the illness onset was fever (82.6%), followed by dry

cough (61.5%) and fatigue (56.9%). Seventy-six patients (69.7%) had underlying

comorbidities, including hypertension (33.9%), diabetes (11.0%), and chronic kidney

disease (9.2%). The first virus RNA detection rate was 24.8% in the fever clinics, and

all patients were reconfirmed by repeated virus RNA testing after admission. Among

109 patients, 91.7% of them had bilateral involvement of the chest radiographs, and

28 patients (25.7%) received high-flow nasal oxygen ventilation, while 31 (28.4%)

died.

Compared with non-ARDS patients with COVID-19, ARDS patients were elder

(mean age, 61 years *vs.* 49 years), and more likely to have coexistent diabetes (20.8%

vs. 1.8%), cerebrovascular disease (11.3% *vs.* 0%), and chronic kidney disease (15.1%

vs. 3.6%). The bilateral involvement in the chest radiographs was identified in all

ARDS patients, but in 83.9% non-ARDS patients. The likelihood to receive high-flow

nasal ventilation for ARDS patients (49.1%) was significantly higher than that for

non-ARDS patients (3.6%). The mortality rate in ARDS patients (49.1%) was also

significantly higher than that in non-ARDS patients (8.9%).

Disease Severity Scores and Laboratory Findings in COVID-19 Patients With and Without ARDS

The disease severity evaluation and laboratory examination of non-ARDS and ARDS patients with COVID-19 on admission were shown in **Table 2**. Compared with non-ARDS subjects, ARDS subjects had significantly higher disease severity on the day of hospital admission (all P values <0.001 for CURB-65, SOFA, and APACHE II). ARDS patients were more likely accompanied by lymphopenia on admission (P value <0.001). Besides, the levels of lactate, neutrophil count, C-reactive protein (CRP), and procalcitonin were significantly higher in ARDS patients than in non-ARDS patients (median lactate level, 1.6 *vs.* 1.1 mmol/L; median neutrophil count level, 4.1 *vs.* 3.2 $\times 10^9$/L; median CRP level, 4.9 *vs.* 2.0 mg/dL; median procalcitonin level, 0.15 *vs.* 0.06 ng/mL). Significant increased levels of blood urea nitrogen, serum fibrinogen, D-dimer, and lactate dehydrogenase in ARDS patients were observed, compared with those in non-ARDS patients (all P values <0.05).

As described in **Figure 1**, the dynamic trajectory in nine laboratory parameters were tracked on Day 1, 3, 7 and 14, respectively. Significant differences in the levels of neutrophil count, lymphocyte count, CRP, procalcitonin, and D-dimer were found between ARDS and non-ARDS patients with COVID-19 (all P values <0.05). From Day 1 to 14, ARDS patients had significantly lower lymphocyte count levels, while the levels of other laboratory findings were higher in ARDS patients.

Clinical Profile and Progression of COVID-19 Patients With ARDS

According to the severity of ARDS, we further analyzed the clinical features, treatments and progression of 53 COVID-19 patients with ARDS. As presented in **Table 3**, the increase in APACHE II, SOFA, and CURB criteria scores occurred concomitantly with the severity of ARDS (all P values <0.001). The levels of lactate, blood urea nitrogen, D-dimer, and lactate dehydrogenase ascended with the severity of ARDS (all P values <0.05), whereas the lymphocyte count levels decreased (P value = 0.045). Patients with moderate ARDS were the most likely to receive glucocorticoid therapy (P value = 0.02) and high-flow nasal oxygen ventilation (P value <0.001), with the longest stays in the hospital (P value = 0.03). Compared to patients with mild ARDS, those with moderate and severe ARDS had higher mortality rates (P value <0.001).

Subsequent survival analysis was shown in **Figure 2**. We found that the antivirus, glucocorticoid, or immunoglobulin treatment did not have any significant effect on the survival of COVID-19 patients with ARDS (all log-rank tests P >0.05).

Discussion

In the present study of ARDS progression in COVID-19, we firstly identified the differences in the clinical manifestations between COVID-19 patients with and without ARDS. Second, the clinical characteristics of COVID-19 patients varied with the severity of ARDS. High mortality rates were found in patients with moderate and severe ARDS. Third, we did not observe any apparent effect of the current therapeutic

interventions on the in-hospital survival of COVID-19 patients with ARDS. Our

findings might highlight the clinical significance in the enhanced attention towards

COVID-19 patients at high risks of ARDS.

To the best of our knowledge, this study is the first to investigate the clinical features

and progression of SARS-CoV-2 infected patients with ARDS. We revealed that elder

patients, or complicated by diabetes, cerebrovascular disease, and chronic kidney

disease, were more likely to develop ARDS. This finding might further explain the

significant association of age and comorbidity conditions with the poor clinical

outcomes in a previous COVID-19 study [7]. In addition, the elevated levels of neutrophil

count, CRP, procalcitonin and D-dimer, but the decreased lymphocyte count levels,

were detected in patients with ARDS, rather than those without ARDS. Similarly, the

levels of lactate and D-dimer increased with the progression of ARDS due to SARS-

CoV-2, while severer lymphopenia occurred over time. Our investigations into these

laboratory indicators were comparable with other COVID-19 studies [6,7,12], suggesting

that cytokine cascade, excessive inflammatory reaction, and coagulation dysfunction

might evolve in the course of ARDS resulted from SARS-CoV-2.

Notably, our understanding of this ARDS progression could be furthered by a recent

autopsy report on a 50-year-old COVID-19 patient with ARDS [13], which was

highlighted by the inflammatory infiltration of lymphocytes in both lungs and the

immune hyperactivation in the patient. Interestingly, no obvious heart injury occurred

in this patient, while the liver injury might be caused by SARS-CoV-2 infection or

medication use [13]. These pathological results were concordant with our clinical

observation of a dysregulated inflammatory and immune state in COVID-19 patients

with ARDS, which might in turn help to guide our medical therapy.

The medical management of ARDS has advanced remarkably during the past decades

[14]. Yet, the general mortality rates of ARDS caused by all etiologies fluctuated from 11%

to 87% [15]. In our study, most patients with COVID-19 received antibiotics and antivirus

treatment, while over half of them were given by glucocorticoid and intravenous

immunoglobulin therapies. Moderate to severe ARDS patients were more likely to use

high-flow nasal oxygen ventilation. Unfortunately, the mortality rate was extremely

high in severe ARDS patients with COVID-19. Notably, the survival of COVID-19

patients with ARDS was not improved by the antivirus, glucocorticoid, or

immunoglobulin treatment. We postulated that two causes might interpret these results:

First, because of the SARS-CoV-2 outbreak within a short period, the designated

hospitals were fast and easily overloaded, with inadequate medical facilities and

insufficient medical staff. Second, in this study, we excluded some COVID-19 patients

who had transferred to other hospitals for advanced life support. However, our findings

were still meaningful. As the low-income and middle-income countries are more

vulnerable to the lack of medical resources, the mortality rate of infectious diseases

may be even higher. Therefore, from a policy perspective, the government should

provide capital, technology, and manpower to curb the epidemic. Meanwhile, in the

front-line epidemic area, limited medical resources should be allocated reasonably and

effectively.

The present study is subjected to several limitations. Due to the retrospective nature of

the present study, a systematic selection bias could be introduced. We could not

completely address the residual confounding factors as well. Although our laboratory

observations showed the significant changes with the time and the severity of ARDS,

the clinical predictive value remained to be determined. In addition, our results on the

effect of the current treatments should be considered with caution, and high-quality

clinical interventional studies are needed. Meanwhile, the benefits of the invasive

ventilation therapy on the disease prognosis should be further investigated. In the future,

a multi-center and follow-up study with a larger cohort is eagerly warranted.

Conclusions

In the current study from one of the designated hospitals in Wuhan, China, the

significant changes with the time and the severity of ARDS were observed in COVID-

19 patients. Moreover, COVID-19 patients with moderate and severe ARDS had high

mortality rates. The current medical treatments might not have a significant effect on

the in-hospital survival of COVID-19 patients with ARDS. Our observations might help

to guide the risk stratification and therapeutic strategy for COVID-19 patients.

Acknowledgement:

We deeply regret and mourn all the lives lost in this disaster of SARS-CoV-2, including our dearest colleague Dr. Wenliang Li. We would like to express our deepest respect to all the people who are currently fighting against the outbreak of COVID-19.

Conflict of Interest Disclosures:

The authors declared no conflict of interest.

Founding/Support:

This study was supported by the Health and Family Planning Commission of Wuhan Municipality, grant number WX18A02.

Role of the Founder/Sponsor:

The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Authors Contributions:

Dr. Chen and Dr. Yu had full access to all the data in the study, and took responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Liu, Sun, Chen, Yu.

Acquisition, analysis, or interpretation of data: Sun, Liu, Li, Chen.

Drafting of the manuscript: Li, Liu.

Critical revision of the manuscript for important intellectual content: Wang, Zhang,

Chen, Yu.

Statistical analysis: Chen.

Obtained funding: Yu.

Supervision: Chen, Yu.

References

1. Hui DS, E IA, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. *Int J Infect Dis* 2020; **91**: 264-6.

2. Velavan TP, Meyer CG. The COVID-19 epidemic. *Trop Med Int Health* 2020.

3. Team C-NIRS. COVID-19, Australia: Epidemiology Report 3 (Reporting week ending 19:00 AEDT 15 February 2020). *Commun Dis Intell (2018)* 2020; **44**.

4. Smith N, Fraser M. Straining the System: Novel Coronavirus (COVID-19) and Preparedness for Concomitant Disasters. *Am J Public Health* 2020: e1-e2.

5. Habibzadeh P, Stoneman EK. The Novel Coronavirus: A Bird's Eye View. *Int J Occup Environ Med* 2020; **11**(2): 65-71.

6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**(10223): 497-506.

7. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020.

8. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med* 2020.

9. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf?sfvrsn=bc7da517_2. Published January 28, 2020. Accessed February 12, 2020.

10. Force ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. *JAMA* 2012; **307**(23): 2526-33.

11. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax* 2003; **58**(5): 377-82.

12. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020; **395**(10223): 514-23.

13. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *The Lancet Respiratory Medicine*.

14. Peck TJ, Hibbert KA. Recent advances in the understanding and management of ARDS. *F1000Res* 2019; **8**.

15. Maca J, Jor O, Holub M, et al. Past and Present ARDS Mortality Rates: A Systematic Review. *Respir Care* 2017; **62**(1): 113-22.

333 **Table 1. Baseline clinical features of subjects with COVID-19.**

	No. (%)			
	Total (*n* = 109)	Non-ARDS (*n* = 56)	ARDS (*n* = 53)	*P*-value[a]
Age, median (IQR), y	55 (43-66)	49 (37-59)	61 (52-70)	**<0.001**
Male	59 (54.1)	31 (55.4)	28 (52.8)	0.79
Entering complaint				
Fever	90 (82.6)	48 (85.7)	42 (79.2)	0.37
Dry cough	67 (61.5)	36 (64.3)	31 (58.5)	0.53
Fatigue	62 (56.9)	26 (46.4)	36 (67.9)	**0.02**
Stethalgia	7 (6.4)	4 (7.1)	3 (5.7)	0.75
Diarrhea	12 (11.0)	6 (10.7)	6 (11.3)	0.92
Comorbidities				
COPD	4 (3.7)	2 (3.6)	2 (3.8)	>0.99
Hypertension	37 (33.9)	16 (28.6)	21 (39.6)	0.22
Diabetes	12 (11.0)	1 (1.8)	11 (20.8)	**0.002**
Cardiovascular disease	7 (6.4)	4 (7.1)	3 (5.7)	>0.99
Cerebrovascular disease	6 (5.5)	0 (0.0)	6 (11.3)	**0.01**
Chronic kidney disease	10 (9.2)	2 (3.6)	8 (15.1)	**0.049**
Onset of symptom to fever clinics, median (IQR), d	4 (2-6)	4 (2-7)	4 (2-6)	0.88
Onset of symptom to hospital admission, median (IQR), d	7 (5-9)	7 (5-9)	7 (5-9)	0.58
Hospital stays, median (IQR), d	15 (11-24)	15 (9-27)	16 (11-23)	0.41
Nucleic acid test (+) in fever clinics	27 (24.8)	12 (21.4)	15 (28.3)	0.41
Bilateral involvement of chest radiographs	100 (91.7)	47 (83.9)	53 (100)	**0.002**
Fever clinics treatment				
Antibiotics	105 (96.3)	55 (98.2)	50 (94.3)	0.35

Antivirus	105 (96.3)	55 (98.2)	50 (94.3)	0.35
Glucocorticoid therapy	43 (39.4)	20 (35.7)	23 (43.4)	0.41
Intravenous immunoglobulin	32 (29.4)	19 (33.9)	13 (24.5)	0.28
In-patient treatment				
Antibiotics	106 (97.2)	53 (94.6)	53 (100.0)	0.24
Antivirus	107 (98.2)	55 (98.2)	52 (98.1)	>0.99
Glucocorticoid therapy	72 (66.1)	35 (62.5)	37 (69.8)	0.42
Intravenous immunoglobulin	61 (56.0)	32 (57.1)	29 (54.7)	0.80
High-flow nasal ventilation	28 (25.7)	2 (3.6)	26 (49.1)	**<0.001**
Death	31 (28.4)	5 (8.9)	26 (49.1)	**<0.001**

334 Abbreviations: ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; IQR, interquartile range;

335 [a] p values indicate differences between non-ARDS and ARDS patients.

337 **Table 2. Severity of COVID-19 and laboratory tests in Non-ARDS and ARDS subjects.**

	Normal range	Median (IQR)			P-value[a]
		Total ($n = 109$)	Non-ARDS ($n = 56$)	ARDS ($n = 53$)	
Severity of illness scores and blood gas analysis on admission to hospital					
CURB-65	NA	0 (0-1)	0 (0-1)	1 (0-2)	**<0.001**
SOFA	NA	2 (1-4)	1 (0-1)	4 (2-5)	**<0.001**
APACHE II	NA	4 (2-8)	2 (1-3)	8 (5-10)	**<0.001**
Lactate, mmol/L	0.5-1.6	1.3 (0.8-2.0)	1.1 (0.8-1.6)	1.6 (1.1-2.2)	**<0.001**
PaO_2:FiO_2, mm Hg	400-500	296 (142-435)	475 (398-524)	145 (108-250)	**<0.001**
Laboratory findings on admission to hospital					
White blood cell count, $\times 10^9$/L	3.5-9.5	5.2 (4.0-7.0)	4.9 (3.8-6.2)	5.4 (4.5-8.0)	0.053
Neutrophil count, $\times 10^9$/L	1.8-6.3	3.6 (2.8-5.6)	3.2 (2.4-4.2)	4.1 (3.1-7.1)	**0.004**
Lymphocyte count, $\times 10^9$/L	1.1-3.2	0.9 (0.5-1.2)	1.0 (0.8-1.4)	0.7 (0.4-1.1)	**<0.001**
C-reactive protein, mg/dL	0-0.5	3.1 (1.1-5.4)	2.0 (0.9-3.2)	4.9 (2.7-6.5)	**<0.001**
Procalcitonin, ng/mL	<0.05	0.09 (0.06-0.20)	0.06 (0.05-0.09)	0.15 (0.08-0.37)	**<0.001**
Blood urea nitrogen, mmol/L	2.8-8	4.3 (3.3-6.5)	3.5 (2.9-4.8)	5.5 (4.0-7.1)	**<0.001**
Creatinine, μmol/L	57-111	65 (55-82)	64 (52-80)	67 (55-83)	0.42
Total bilirubin, mmol/L	0-21	9.0 (6.5-13.4)	8.3 (6.8-11.7)	10.5 (6.2-14.8)	0.23
Alanine aminotransferase, U/L	9-50	23 (15-36)	23 (14-41)	24 (16-31)	0.82
Aspartate aminotransferase, U/L	15-40	30 (21-40)	29 (19-38)	31 (25-44)	0.17
Fibrinogen, g/L	2-4	3.1 (2.7-3.6)	2.9 (2.7-3.3)	3.4 (2.9-3.9)	**0.001**
D-dimer, mg/L	0-500	570 (300-1178)	370 (250-650)	940 (470-1905)	**<0.001**
Lactate dehydrogenase, U/L	135-225	238 (185-341)	209 (183-267)	264 (190-448)	**0.011**
Creatine kinase, U/L	<190	91 (52-178)	100 (53-183)	83 (49-169)	0.29

| Creatine kinase–MB, U/L | <25 | 9.0 (6.1-14.8) | 8.5 (6.0-12.5) | 10.4 (7.0-15.1) | 0.28 |

342   **Table 3. Clinical characteristics, laboratory findings, and treatment according to the severity of ARDS.**

	Normal range	Median (IQR)			P-value[a]
		Mild ARDS (*n* = 19)	**Moderate ARDS** (*n* = 24)	**Severe ARDS** (*n* = 10)	
Age, y	NA	52 (46-63)	65 (57-70)	67 (55-71)	**0.04**
Severity of illness scores and blood gas analysis on admission to hospital					
CURB-65	NA	0 (0-1)	1 (1-2)	2 (1-3)	**<0.001**
SOFA	NA	2 (2-3)	4 (3-5)	6 (5-6)	**<0.001**
APACHE II	NA	3 (2-6)	8 (7-12)	10 (8-13)	**<0.001**
Lactate, mmol/L	0.5-1.6	1.2 (0.8-1.7)	1.8 (1.1-2.3)	5.2 (2.0-10.0)	**<0.001**
PaO_2:FiO_2, mm Hg	400-500	276 (247-280)	140 (117-153)	85 (57-88)	**<0.001**
Laboratory findings on admission to hospital					
White blood cell count, ×109/L	3.5-9.5	4.6 (3.8-5.0)	7.3 (5.2-10.5)	7.0 (4.6-8.0)	**0.006**
Neutrophil count, ×109/L	1.8-6.3	3.2 (2.3-3.8)	6.0 (4.2-9.0)	5.3 (3.7-7.3)	**0.002**
Lymphocyte count, ×109/L	1.1-3.2	0.9 (0.7-1.3)	0.6 (0.4-0.9)	0.5 (0.4-0.8)	**0.045**
C-reactive protein, mg/dL	0-0.5	4.1 (2.2-5.9)	4.1 (1.9-9.7)	6.7 (5.5-12.2)	**0.027**
Procalcitonin, ng/mL	<0.05	0.10 (0.08-0.21)	0.16 (0.08-0.55)	0.28 (0.22-1.52)	0.09
Blood urea nitrogen, mmol/L	2.8-8	4.5 (3.5-6.1)	5.6 (4.5-7.7)	7.1 (6.0-8.0)	**0.03**
Creatinine, μmol/L	57-111	67 (58-74)	65 (54-99)	70 (55-80)	0.89
Total bilirubin, mmol/L	0-21	7.9 (5.8-10.4)	13.2 (9.3-18.6)	13.2 (6.2-13.5)	0.07
Alanine aminotransferase, U/L	9-50	24 (15-34)	24 (21-27)	21 (15-32)	0.90
Aspartate aminotransferase, U/L	15-40	29 (21-43)	34 (27-44)	29 (27-36)	0.45
Fibrinogen, g/L	2-4	3.3 (2.8-3.6)	3.4 (2.9-4.3)	3.6 (3.4-4.1)	0.41
D-dimer, mg/L	0-500	330 (220-798)	1220 (695-4035)	1385 (985-7550)	**<0.001**

Lactate dehydrogenase, U/L	135-225	190 (166-238)	347 (255-504)	458 (286-549)	**0.001**
Creatine kinase, U/L	<190	69 (44-119)	92 (58-185)	66 (53-188)	0.49
Creatine kinase–MB, U/L	<25	8.0 (6.5-11.6)	11.1 (6.8-16.1)	10.9 (8.9-12.0)	0.37
In-patient treatment, *n* (%)					
Ribavirin	NA	18 (94.7)	18 (75.0)	10 (100.0)	0.08
Oseltamivir	NA	5 (26.3)	8 (33.3)	1 (10.0)	0.43
Arbidol	NA	3 (15.8)	2 (8.3)	1 (10.0)	0.85
Glucocorticoid therapy	NA	9 (47.4)	21 (87.5)	7 (70.0)	**0.02**
Intravenous immunoglobulin	NA	13 (68.4)	9 (37.5)	7 (70.0)	0.08
High-flow nasal ventilation, *n* (%)	NA	1 (5.3)	19 (79.2)	6 (60.0)	**<0.001**
Hospital stays, d	NA	18 (13-25)	18 (15-25)	11 (10-13)	**0.03**
Death, *n* (%)	NA	1 (5.3)	15 (62.5)	10 (100.0)	**<0.001**

Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, acute respiratory distress syndrome; FiO_2, fraction of

inspired oxygen; IQR, interquartile range; NA, not available; PaO_2, partial pressure of oxygen; SOFA, Sequential Organ Failure Assessment

[a] *p* values indicate differences among mild, moderate, and severe ARDS patients.

Figure legends

Figure 1. Timeline charts illustrate the laboratory parameters in 109 patients with COVID-19 (56 non-ARDS and 53 ARDS) on day 1, day 3, day

7, and day 14 after admission. The dash lines in black show the upper normal limit of each parameter, and the dash line in red shows the lower

normal limit of lymphocyte count.

* P <0.05 for non-ARDS *vs*. ARDS.

Figure 2. Kaplan-Meier survival curves for 53 COVID-19 patients concurrent ARDS. (A) Ribavirin; (B) Oseltamivir; (C) Arbidol; (D)

Glucocorticoid therapy; (E) Intravenous immunoglobulin.